WRAIR And Maas BiolAB Manufacture Neuroprotective Cyclosporin Formula Mitogard®
Published: Dec 14, 2006
SILVER SPRING, Md. & ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Maas BiolAB and the Pilot Bioproduction Facility (PBF) of the Walter Reed Army Institute of Research (WRAIR) manufactured Mitogard®, a proprietary cyclosporin formulation. Mitogard® was shown by WRAIR researchers to be neuroprotective in models of traumatic brain injury and seizure-induced brain injury from organophosphate nerve agents. The scale up production of Mitogard® under current good manufacturing practices (cGMPs) is the first drug preparation by the PBF, which previously focused exclusively on vaccines.